XenoTech Provides Pooled Human Liver Homogenate for Evaluation of Drug Metabolizing Enzymes and Proteins
SEKISUI XenoTech now offers pooled human liver homogenate as part of its extensive catalog of cell and tissue-based products. This test system is ideal for metabolism identification when responsible enzymes are not known, proteomic assays, enzymatic activity studies, etc.
SEKISUI XenoTech’s human liver homogenate is comprised of tissue from 20 donors that is homogenized, centrifuged at low speed to remove connective tissue, large pieces of cell membranes and intact cell nuclei, and diluted to a constant protein concentration. By removing the additional centrifugation steps that are typical in S9 or microsomal preparations, the resulting fraction is rich with drug metabolizing enzymes and proteins.
SEKISUI XenoTech, LLC is a global Contract Research Organization utilized by 98% of top pharma companies and numerous other organizations. For almost 25 years, the company has offered proven drug development expertise, providing an ever-evolving selection of cell and tissue-based products, screening, radiolabeling, API manufacturing, in vitro ADME Tox and pharmacology, in vivo ADME Tox and QWBA, metabolite ID and production, bioanalytical services and consulting. SEKISUI XenoTech’s product selection includes a wide range of high-quality unique and standard reagents, including subcellular fractions, hepatocytes, media, tissue samples, cell lines, recombinant enzymes, substrates & metabolites and more. The company also regularly prepares and delivers custom-designed products and services in response to client requests. For additional information, please refer to the company’s website at www.xenotech.com.